Psychedelic Science in the 21st Century! Apr 15-18, 2010
The big 2010 conference, sponsored by MAPS and held in San Jose, California

Erowid References Database

Semple DM, Ebmeier KP, Glabus MF, O'Carroll RE, Johnstone EC. 
“Reduced in vivo binding to the serotonin transporter in the cerebral cortex of MDMA ('ecstasy') users”. 
Br J Psychiatry. 1999 Jul;175:63-9.
Abstract
BACKGROUND: The use of MDMA ('ecstasy') is common among young people in Western countries. Animal models of MDMA toxicity suggest a loss of serotonergic neurons, and potentially implicate in the development of significant psychiatric morbidity in humans. AIMS: To test whether long-term use of MDMA can produce abnormalities in cerebral serotonin, but not dopamine, transporter binding measured by single photon emission computed tomography (SPECT).
METHODS: Ten male regular ecstasy users and 10 well-matched controls recruited from the same community sources participated in SPECT with the serotonin transporter (SERT) ligand [123I] beta-CIT. Dopamine transporter binding was determined from scans acquired 23 hours after injection of the tracer.
RESULTS: Ecstasy users showed a cortical reduction of SERT binding, particularly prominent in primary sensory-motor cortex, with normal dopamine transporter binding in lenticular nuclei.
CONCLUSIONS: This cross-sectional association study provides suggestive evidence for specific, at least temporary, serotonergic neurotoxicity of MDMA in humans.




Erowid.org Plants & Drugs Mind & Spirit Freedom & Law Arts & Sciences Search About Erowid and Feedback Library & Bookstore Copyrights Memberships noref